Role of Next-Generation Sequencing in the Treatment of Metastatic Apocrine Carcinoma: A Rare Entity

Primary apocrine adenocarcinoma, a rare malignancy, is an aggressive tumor rarely reported. It has diagnostic and treatment challenges as it is difficult to distinguish it from metastases due to breast carcinoma. Currently, no data are available for the use of next-generation sequencing to identify the possibility of targeted therapies for metastatic disease. Only a few cases are reported, hence, no consensus has been developed for treatment guidelines, and a prognosis has not been established. We present here a case of this rare tumor, its treatment course, and the role of next-generation sequencing for the use of targeted therapy.